Health
-
July 15: India’s pharmaceutical sector is witnessing a strong rise in innovation activity, with India-origin…
-
Ganjam, July 14 (UDN): The Ganjam district administration has issued a high alert across the district…
-
Bhubaneswar, July 13 (UDN): Odisha has accelerated its efforts towards tuberculosis elimination through an extensive…
-
Guwahati, July 10: The Assam government has presented a budget focused on employment generation, infrastructure…
-
New Delhi, July 10: The government has announced that formulations containing high levels of alcohol…
-
Milan, Italy, July 08 — Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has today announced the publication of preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat methylmalonic acidemia (MMA), a severe inherited metabolic disorder. The findings, published in the Journal of Hepatology, show that a single systemic administration of a lentiviral vector encoding the MMUT gene led to sustained improvements in disease features in a validated mouse model of MMA, with effects lasting for the average lifespan of laboratory mice. Since the mice were treated when young, the study supports the durability of the gene therapy through postnatal growth and maturation of the liver. MMA is caused by a deficiency of methylmalonyl-CoA mutase, an enzyme that plays a critical role in the body’s metabolism of food. Its absence results in the accumulation of toxic metabolites that lead to recurrent metabolic crises, growth failure, neurological impairment,…
-
Rourkela, July 8 (UDN): Researchers at NIT Rourkela have developed a smart bandage that could…
-
Bhopal, July 8: The Madhya Pradesh Government is working to expand digital healthcare services to…
-
Lucknow, July 8: The Uttar Pradesh government has launched a new cashless healthcare scheme aimed…
-
New Delhi, July 8: The Government has approved Navi Mumbai International Airport as an authorised…